Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 23
Chinese Journal of Hepatology ; (12): 304-308, 2022.
Article in Chinese | WPRIM | ID: wpr-935942


Objective: To explore the efficacy of entecavir antiviral therapy on the degree of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) combined with chronic hepatitis B (CHB) in Tibet region. Methods: HBeAg-positive CHB patients who were treated with entecavir in the outpatient and inpatient Department of Infectious Diseases of the Tibet Autonomous Region people's Hospital between January 2018 to December 2019 were retrospectively analyzed. Among the 140 subjects with CHB, 95 cases were CHB alone, and the other 45 cases were diagnosed as CHB combined with NAFLD by ultrasound. All patients were given entecavir 0.5 mg orally once daily on an empty stomach for 48 weeks. HBeAg negative conversion rate, blood glucose, blood lipid, liver function and the degree of liver fibrosis were compared between the two groups at the 12th, 24th and 48th weeks of treatment to evaluate the virological response. SPSS 19.0 statistical software was used to process the data. Measurement data were expressed as mean ± standard deviation (x¯±s). Descriptive statistical analysis was used for t-test, and the categorical variables were expressed as percentage (%) and χ2 test. A p-value < 0.05 was considered as statistically significant. Results: After 48 weeks of treatment, the HBeAg and HBV DNA negative conversion rate were significantly better in patients with CHB alone (group B) than CHB combined with NAFLD (group A), that is to say, HBeAg negative conversion rate in group A and B patients were 28.90% and 40%, respectively, and group B was better than group A. HBV DNA negative conversion rate was significantly elevated in group B (83.2%) than group A (64.4%), with statistical significance (P<0.05), and the difference between the both groups was statistically significant. Alanine aminotransferase level was significantly decreased in patients with CHB alone than patients with CHB combined with NAFLD. Aspartate aminotransferase/platelet ratio index was significantly decreased after treatment than before treatment in both group of patients, and the depletion was more pronounced in CHB alone group. Liver stiffness values were significantly decreased in patients with CHB combined with NAFLD than CHB alone group. Moreover, liver stiffness values was higher in group A than group B before treatment under the influence of fat attenuation factors, and the differences before treatment and after treatment were 3.50±4.66 and 2.05±2.53, respectively; however, group B was not affected by fat attenuation factors, so LSM value reduction in group A was more obvious, and the differences were statistically significant. There was no statistically significant difference in blood glucose and blood lipids levels before and after treatment between the two groups. Conclusion: NAFLD has a certain effect on antiviral therapy and liver fibrosis in patients with CHB, i.e., the effect of antiviral therapy in patients with CHB alone is better than patients with CHB combined with NAFLD. Patients with CHB combined with NAFLD when treated with antiviral therapy had a significantly greater degree of liver stiffness reduction than patients with CHB alone. Therefore, it is necessary to actively intervene the risk factors associated with NAFLD according to the actual situation of different individuals to improve clinical efficacy of antiviral therapy.

Humans , Antiviral Agents/therapeutic use , DNA, Viral , Guanine/analogs & derivatives , Hepatitis B e Antigens , Hepatitis B, Chronic/drug therapy , Liver Cirrhosis/complications , Non-alcoholic Fatty Liver Disease/drug therapy , Retrospective Studies , Tibet , Treatment Outcome
Chinese Journal of Hepatology ; (12): 74-80, 2022.
Article in Chinese | WPRIM | ID: wpr-935911


Objective: To investigate whether the selective cyclooxygenase-2 enzyme inhibitors celecoxib has protective effect on the liver of rats with type 2 diabetes mellitus (T2DM) combined with nonalcoholic steatohepatitis (NASH) via inhibiting the expression of Rho/ROCK pathway. Methods: Forty male SD rats were randomly divided into four groups: type 2 diabetes mellitus combined with nonalcoholic steatohepatitis (T2DM-NASH) group, T2DM-NASH + celecoxib group, control group, and control+celecoxib group. The T2DM-NASH and T2DM-NASH + celecoxib groups were fed with high-sugar and fat diet, and the control group and control + celecoxib group were fed with basal diet (25 kJ/kg). Four weeks later, streptozotocin (STZ, 30 mg/kg) was intraperitoneally injected into the NASH group and T2DM-NASH + celecoxib group to induce T2DM model, and the control group and control + celecoxib group were intraperitoneally injected with isovolumic citric acid-sodium citrate buffer. Four weeks after STZ injection, the T2DM-NASH + celecoxib group and the control + celecoxib group were gavaged with celecoxib (10 mg·kg·d) dissolved in normal saline for 4 weeks, and the remaining two groups of rats were gavaged with isovolumic normal saline for 4 weeks. Animals were sacrificed at the end of the 12- weeks, and the liver tissue was collected. Liver pathological changes were observed by HE staining. The expressions of RhoA, RhoA, ROCK1 and ROCK2 proteins in liver were detected by immunohistochemistry and western blot. The expressional condition of RhoA, ROCK1 and ROCK2 mRNA in liver were detected by real-time quantitative PCR. The differences were compared between protein and mRNA expression among the groups by analysis of variance and t-test. Results: Compared with the control group and the control + celecoxib group, the liver tissue of the T2DM-NASH group and the T2DM-NASH + celecoxib group had severe steatosis, and there was partial inflammatory cell infiltration under the light microscope. The expression levels of RhoA, ROCK1 and ROCK2 protein and mRNA were significantly increased (P < 0.05) in each liver tissue, while liver steatosis was reduced to certain extent in T2DM-NASH + celecoxib group than T2DM-NASH group, and the expression levels of RhoA, ROCK1 and ROCK2 protein and mRNA were decreased in each liver tissue of T2DM-NASH group (P < 0.05). Conclusion: The selective cyclooxygenase-2 enzyme inhibitors celecoxib has a protective effect on the liver of rats with T2DM-NASH, and its effect may be achieved by inhibiting the expression of Rho/ROCK pathway.

Animals , Male , Rats , Cyclooxygenase 2/therapeutic use , Cyclooxygenase 2 Inhibitors/therapeutic use , Diabetes Mellitus, Type 2/drug therapy , Liver , Non-alcoholic Fatty Liver Disease/drug therapy , Rats, Sprague-Dawley
Article in Chinese | WPRIM | ID: wpr-928143


This study aimed to investigate the effect of Tibetan medicine Ershiwuwei Songshi Pills(ESP) on the intestinal flora of non-alcoholic steatohepatitis(NASH) mice. Forty-eight male C57 BL/6 mice were randomly divided into the control group, model(methionine-choline-deficient, MCD) group, high-(0.8 g·kg~(-1)), medium-(0.4 g·kg~(-1)), and low-dose(0.2 g·kg~(-1)) ESP groups, and pioglitazone(PGZ, 10 mg·kg~(-1)) group, with eight mice in each group. Mice in the control group were fed with normal diet, while those in the remaining five groups with MCD diet for five weeks for inducing NASH. During modeling, they were gavaged with the corresponding drugs. The changes in body mass, daily water intake, and daily food intake were recorded. At the end of the experiment, the liver tissues were collected and stained with hematoxylin-eosin(HE) for observing the pathological changes, followed by oil red O staining for observing fat accumulation in the liver. The levels of serum aspartate aminotransferase(AST) and alanine aminotransferase(ALT) and triglyceride(TG) in liver tissue were measured. The changes in intestinal flora of mice were determined using 16 S rRNA high-throughput sequencing technology. The results showed that compared with the model group, the high-, medium-and low-dose ESP groups and the PGZ group exhibited significantly lowered AST and ALT in serum and TG in liver tissues and alleviated hepatocellular steatosis and fat accumulation in the liver. As demonstrated by 16 S rRNA sequencing, the abundance index and diversity of intestinal flora decreased in the model group, while those increased in the ESP groups. Besides, the Firmicutes to Bacteroidetes ratio decreased at the phylum level. In the alteration of the composition of intestinal flora, ESP reduced the abundance of Erysipelotrichia and Faecalibaculum but increased the abundance of Desulfovibrionaceae, Rikenellaceae, Lachnospiraceae, and Ruminococcaceae. This study has revealed that ESP has a protective effect against NASH induced by MCD diet, which may be related to its regulation of the changes in intestinal flora, alteration of the composition of intestinal flora, and inhibition of the intestinal dysbiosis.

Animals , Male , Mice , Disease Models, Animal , Gastrointestinal Microbiome , Liver , Medicine, Tibetan Traditional , Mice, Inbred C57BL , Non-alcoholic Fatty Liver Disease/drug therapy
Article in Chinese | WPRIM | ID: wpr-927873


Objective To explore the potential targets of triclosan in the treatment of nonalcoholic fatty liver disease(NAFLD) and to provide new clues for the future research on the application of triclosan. Methods The targets of triclosan and NAFLD were obtained via network pharmacology.The protein-protein interaction network was constructed with the common targets shared by triclosan and NAFLD.The affinity of triclosan to targets was verified through molecular docking.Gene ontology(GO) annotation and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment were carried out to analyze the key targets and the potential mechanism of action.NAFLD model was established by feeding male C57BL/6J mice with high-fat diet for 12 weeks.The mice were randomly assigned into a model group and a triclosan group [400 mg/(kg·d),gavage once a day for 8 weeks].The hematoxylin-eosin(HE) staining was used for observation of the pathological changes and oil red O staining for observation of fat deposition in mouse liver.Western blotting was employed to detect the protein level of peroxisome proliferator-activated receptor alpha(PPARα) in the liver tissue. Results Triclosan and NAFLD had 34 common targets,19 of which may be the potential targets for the treatment,including albumin(ALB),PPARα,mitogen-activated protein kinase 8(MAPK8),and fatty acid synthase.Molecular docking predicted that ALB,PPARα,and MAPK8 had good binding ability to triclosan.KEGG pathway enrichment showcased that the targets were mainly enriched in peroxisome proliferator-activated receptor signaling pathway,in which ALB and MAPK8 were not involved.Triclosan alleviated the balloon-like change and lipid droplet vacuole,decreased the lipid droplet area,and up-regulated the expression level of PPARα in mouse liver tissue. Conclusion PPARα is a key target of triclosan in the treatment of NAFLD,which may be involved in fatty acid oxidation through the peroxisome proliferator activated receptor signaling pathway.

Animals , Male , Mice , Liver/pathology , Mice, Inbred C57BL , Molecular Docking Simulation , Network Pharmacology , Non-alcoholic Fatty Liver Disease/drug therapy , PPAR alpha/therapeutic use , Triclosan/therapeutic use
Rev. cuba. med ; 60(3): e1678, 2021. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1347511


Introducción: La enfermedad por depósito graso no alcohólica constituye una pandemia del mundo contemporáneo. Su espectro silente atraviesa estadios de cronicidad y puede llegar a la cirrosis hepática y sobre esta pudiera desarrollarse un hepatocarcinoma. No existen tratamientos y solo se puede actuar sobre los factores de riesgo. Objetivo: Evaluar el efecto citohepatoprotector y antifibrótico del propóleos rojo cubano oral en pacientes con esteatohepatitis no alcohólica. Métodos: Se realizó un estudio longitudinal prospectivo en pacientes seleccionados de las consultas de Gastroenterología, Endocrinología y Medicina Interna del Hospital Clínico Quirúrgico Hermanos Ameijeiras durante el periodo de abril 2017 a abril 2018. El universo de estudio fue de 120 pacientes con diagnóstico imagenológico de hígado graso. La muestra quedó conformada por 70 pacientes con diagnóstico de hígado graso, y que cumplieron criterios de inclusión y exclusión. Las pruebas estadísticas aplicadas fueron análisis de frecuencia y porcentaje para las variables demográficas. La prueba T para las muestras relacionadas evaluó el comportamiento enzimático al inicio y al final del tratamiento y los cambios elastográficos fueron analizados mediante test de Kappa y porcentaje. Resultados: Las variables bioquímicas estudiadas mostraron una disminución estadísticamente significativa al final del tratamiento. Los cambios elastográficos al final del estudio evidenciaron la efectividad del tratamiento, en el cual el 91,4 por ciento de los pacientes evolucionaron hacia el menor grado de fibrosis. Conclusiones: El propóleos rojo cubano demostró ser un apifármaco con acción citohepatoprotectora y antifibrótica de valor terapéutico(AU)

Introduction: Nonalcoholic fat deposition disease is a pandemic in the contemporary world. Its silent spectrum goes through stages of chronicity and it can reach liver cirrhosis and on this a hepatic carcinoma could develop. There are no treatments and medical handling can act on only risk factors. Objective: To evaluate cytohepatoprotective and antifibrotic effect of oral Cuban red propolis in patients with nonalcoholic steatohepatitis. Methods: A prospective longitudinal study was carried out in selected patients from the Gastroenterology, Endocrinology and Internal Medicine consultations at Hermanos Ameijeiras Clinical Surgical Hospital from April 2017 to April 2018. The study universe was 120 patients with imaging diagnosis of fatty liver. The sample consisted of 70 patients with fatty liver diagnosis, who met the inclusion and exclusion criteria. Frequency and percentage analysis for the demographic variables were the statistical tests applied. The T test for the related samples evaluated the enzymatic behavior at the beginning and at the end of the treatment and the elastography changes were analyzed using Kappa and percentage tests. Results: The biochemical variables studied showed statistically significant decrease at the end of the treatment, which evidenced the effectiveness of the treatment. 91.4 percent of the patients progressed to a lower degree of fibrosis. Conclusions: Cuban red propolis proved to be a therapeutic drug with cytohepathoprotective and antifibrotic action(AU)

Humans , Elasticity Imaging Techniques/methods , Apitherapy , Non-alcoholic Fatty Liver Disease/drug therapy , Non-alcoholic Fatty Liver Disease/diagnostic imaging , Prospective Studies , Risk Factors , Longitudinal Studies
Journal of Integrative Medicine ; (12): 428-438, 2021.
Article in English | WPRIM | ID: wpr-888771


OBJECTIVE@#High-fat diet (HFD) and inflammation are two key contributors to nonalcoholic fatty liver disease (NAFLD). Shenling Baizhu powder (SLBZP), a classical herbal compound, has been successfully used to alleviate NAFLD. However, its specific mechanisms are not fully understood. In this study, we assessed the anti-NAFLD effect of SLBZP in vivo.@*METHODS@#Rats were fed an HFD with or without SLBZP or with probiotics. At the end of week 16, an echo magnetic resonance imaging (EchoMRI) body composition analyser was used to quantitatively analyse body composition; a micro-computed tomography (micro-CT) imaging system was used to evaluate whole body and liver fat; and the Moor full-field laser perfusion imager 2 was used to assess liver microcirculation, after which, all rats were sacrificed. Then, biochemical indicators in the blood and the ultrastructure of rat livers were evaluated. Protein expression related to the liver Toll-like receptor 4 (TLR4)/Nod-like receptor family pyrin domain-containing 3 (NLRP3) signalling pathway was assessed using Western blot analysis. Further, high-throughput screening of 29 related inflammatory factors in liver tissue was performed using a cytokine array.@*RESULTS@#SLBZP supplementation reduced body weight, serum free fatty acid, and insulin resistance index (P < 0.05). It also ameliorated liver microcirculation and ultrastructural abnormalities. EchoMRI and micro-CT quantitative analyses showed that treatment with SLBZP reduced fat mass and visceral fat (P < 0.05 and P < 0.01, respectively). In addition, SLBZP decreased the expression of lipopolysaccharide (LPS)-activated TLR4/NLRP3 signalling pathway-related proteins and altered the expression levels of some inflammatory cytokines in liver tissues.@*CONCLUSION@#SLBZP can inhibit NLRP3 inflammasome activation and interleukin-1β release by suppressing LPS-induced TLR4 expression in rats with HFD-induced NAFLD. Thus, SLBZP may be beneficial for the prevention and treatment of inflammatory damage and associated diseases.

Animals , Rats , Liver , NLR Family, Pyrin Domain-Containing 3 Protein , Non-alcoholic Fatty Liver Disease/drug therapy , Powders , Toll-Like Receptor 4 , X-Ray Microtomography
Rev. chil. endocrinol. diabetes ; 14(1): 7-13, 2021. tab, ilus
Article in Spanish | LILACS | ID: biblio-1146465


INTRODUCCIÓN: La enfermedad del hígado graso no alcohólico (EHGNA) es la forma más común de enfermedad hepática. A nivel celular se caracteriza por la acumulación de triglicéridos (TG) en forma de gotas lipídicas (GL) dando lugar a esteatosis e inflamación. Entre los factores relevantes para la síntesis de TG se encuentran las enzimas DGAT1/2 que catalizan la etapa final de la síntesis de TG, y la proteína FABP4 que transporta lípidos intracelulares y se expresa en modelos de enfermedad hepática dependiente de obesidad. Por otra parte, TNF-α es una reconocida citoquina involucrada en el proceso inflamatorio en la EHGNA. La medicina popular del norte de Chile ha utilizado la planta Lampaya medicinalis Phil. (Verbenaceae) para el tratamiento de algunas enfermedades inflamatorias. OBJETIVO: Evaluar el efecto de un extracto hidroalcóholico de lampaya (EHL) sobre la esteatosis y expresión de marcadores de inflamación en hepatocitos tratados con ácidos grasos. Diseño experimental: Estudio in vitro en cultivos de la línea celular humana HepG2 tratadas con ácido oleico (AO) y ácido palmítico (AP). MÉTODOS: Se incubó hepatocitos HepG2 con AO/AP por 24 horas en presencia o no de EHL. Se evaluó la presencia de GL y el contenido de TG intracelulares por Oil Red O y Nile Red, respectivamente. La expresión de DGAT1/2, FABP4 y TNF-α fue evaluada por qPCR. RESULTADOS: Los hepatocitos tratados con AO/AP mostraron un aumento en las GL y TG, así como una mayor expresión de DGAT2 en comparación al control. El cotratamiento con EHL revirtió los efectos inducidos por AO/AP. CONCLUSIONES: EHL revierte el incremento en las GL, TG y en la expresión de DGAT2 inducido por AO/AP en células HepG2. Estos hallazgos sugieren un efecto hepatoprotector de la Lampaya contra la esteatosis, y apoyarían su uso complementario en el tratamiento de patologías con componente inflamatorio como la EHGNA.

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease. At the cellular level, it is characterized by the accumulation of triglycerides (TG) in the form of lipid droplets (LD), which leads to steatosis and inflammation. Among relevant factors for TG synthesis are the enzymes DGAT1/2 catalyzing the final stage of TG synthesis, and the protein FABP4 which transports intracellular lipids and is expressed in cell models of obesity-dependent liver disease. Additionally, TNF-α is a cytokine involved in the inflammatory process associated to NAFDL. Lampaya medicinalis Phil. (Verbenaceae) is a plant used in folk medicine in northern Chile to treat some inflammatory diseases. OBJECTIVE: To evaluate the effect of the hydroalcoholic extract of lampaya (HEL) on steatosis and the expression of inflammatory markers in hepatocytes treated with fatty acids. Study design: In vitro study in cultures of the human HepG2 cell line treated with oleic acid (OA) and palmitic acid (PA). METHODS: HepG2 hepatocytes were incubated with OA/PA for 24 hours in the presence and absence of HEL. The formation of LD and the accumulation of intracellular TG were assessed by Oil Red O and Nile Red, respectively. The expression of DGAT1/2, FABP4 and TNF-α was assessed by qPCR. RESULTS: The treatment with OA/PA increased the levels of LD and TG as well as the expression of DGAT2 in HepG2 hepatocytes compared to control cells. HEL cotreatment counteracted OA/PA-induced effects. CONCLUSIONS: HEL prevents the increase in LD and TG levels and DGAT2 expression induced by OA/PA in HepG2 cells. These findings suggest that lampaya may have a protective effect against hepatic steatosis, which would support its complementary use in the treatment of pathologies associated with inflammation, such as NAFLD.

Humans , Plant Extracts/pharmacology , Hepatocytes/drug effects , Verbenaceae/chemistry , Non-alcoholic Fatty Liver Disease/drug therapy , Triglycerides/analysis , In Vitro Techniques , Plant Extracts/therapeutic use , Cell Survival , Polymerase Chain Reaction , Cell Culture Techniques , Oleic Acid , Ethanol/chemistry , Hep G2 Cells/drug effects , Inflammation
Braz. j. med. biol. res ; 54(10): e11391, 2021. tab, graf
Article in English | LILACS | ID: biblio-1285650


Nonalcoholic fatty liver disease (NAFLD), characterized by hepatosteatosis and steatohepatitis, is intrinsically related to obesity. Our previous study reported on the anti-obese activity of α,β-amyrin (AMY), a pentacyclic triterpene isolated from Protium heptaphyllum. This study investigated its ability to prevent fatty liver and the underlying mechanism using the mouse model of NAFLD. NAFLD was induced in male Swiss mice fed a high fat diet (HFD) for 15 weeks. The controls were fed a normal chow diet (ND). The mice were simultaneously treated with AMY at 10 and 20 mg/kg or fenofibrate at 50 mg/kg. Lipid levels along with metabolic and inflammatory parameters were assessed in liver and serum. The liver sections were histologically examined using H&E staining. RT-qPCR and western blotting assays were performed to analyze signaling mechanisms. Mice fed HFD developed severe hepatic steatosis with elevated triglycerides and lipid droplets compared with ND controls. This was associated with a decrease in AMP-activated protein kinase (AMPK) activity, an increase of mechanistic target of rapamycin complex 1 (mTORC1) signaling, and enhanced sterol regulatory element binding protein 1 (SREBP1) expression, which have roles in lipogenesis, inhibition of lipolysis, and inflammatory response. AMY treatment reversed these signaling activities and decreased the severity of hepatic steatosis and inflammatory response, evidenced by serum and liver parameters as well as histological findings. AMY-induced reduction in hepatic steatosis seemed to involve AMPK-mTORC1-SREBP1 signaling pathways, which supported its beneficial role in the prevention and treatment of NAFLD.

Animals , Male , Rabbits , Insulin Resistance , Non-alcoholic Fatty Liver Disease/prevention & control , Non-alcoholic Fatty Liver Disease/drug therapy , Oleanolic Acid/analogs & derivatives , Sterol Regulatory Element Binding Protein 1 , AMP-Activated Protein Kinases , Diet, High-Fat/adverse effects , Mechanistic Target of Rapamycin Complex 1 , Liver , Mice, Inbred C57BL
Journal of Integrative Medicine ; (12): 545-554, 2021.
Article in English | WPRIM | ID: wpr-922528


OBJECTIVE@#To investigate effects of berberine (BBR) on cholesterol synthesis in HepG2 cells with free fatty acid (FFA)-induced steatosis and to explore the underlying mechanisms.@*METHODS@#A steatosis cell model was induced in HepG2 cell line fed with FFA (0.5 mmol/L, oleic acid:palmitic acid = 2:1), and then treated with three concentrations of BBR; cell viability was assessed with cell counting kit-8 assays. Lipid accumulation in cells was observed through oil red O staining and total cholesterol (TC) content was detected by TC assay. The effects of BBR on cholesterol synthesis mediators were assessed by Western blotting and quantitative polymerase chain reaction. In addition, both silent information regulator 1 (SIRT1) and forkhead box transcription factor O1 (FoxO1) inhibitors were employed for validation.@*RESULTS@#FFA-induced steatosis was successfully established in HepG2 cells. Lipid accumulation and TC content in BBR groups were significantly lower (P < 0.05, P < 0.01), associated with significantly higher mRNA and protein levels of SIRT1(P < 0.05, P < 0.01), significantly lower sterol regulatory element-binding protein 2 (SREBP2) and 3-hydroxy 3-methylglutaryl-CoA reductase levels (P < 0.05, P < 0.01), as well as higher Acetyl-FoxO1 protein level (P < 0.05, P < 0.01) compared to the FFA only group. Both SIRT1 inhibitor SIRT1-IN-1 and FoxO1 inhibitor AS1842856 blocked the BBR-mediated therapeutic effects. Immunofluorescence showed that the increased SIRT1 expression increased FoxO1 deacetylation, and promoted its nuclear translocation.@*CONCLUSION@#BBR can mitigate FFA-induced steatosis in HepG2 cells by activating SIRT1-FoxO1-SREBP2 signal pathway. BBR may emerge as a potential drug candidate for treating nonalcoholic hepatic steatosis.

Humans , Berberine/pharmacology , Cholesterol , Forkhead Box Protein O1/genetics , Non-alcoholic Fatty Liver Disease/drug therapy , Sirtuin 1/genetics , Sterol Regulatory Element Binding Proteins
Arq. gastroenterol ; 56(2): 184-190, Apr.-June 2019. tab, graf
Article in English | LILACS | ID: biblio-1019457


ABSTRACT BACKGROUND: Nowadays, pharmacological treatment of non-alcoholic fatty liver disease (NAFLD) is still limited and it is based on the treatment of conditions associated comorbities. Oxidative stress and insulin resistance are the mechanisms that seem to be mostly involved in its pathogenesis. OBJECTIVE: To evaluate the efficacy of N-acetylcysteine (NAC) in combination with metformin (MTF) and/or ursodeoxycholic acid (UDCA) for treatment of non-alcoholic steatohepatitis (NASH). METHODS: Open-label multicenter randomized trial was conducted for 48 weeks. It included patients with biopsy-proven NASH. The patients were randomized into three groups: NAC (1.2 g) + UDCA (15 mg/kg) + MTF (850-1500 mg/day) (n=26); UDCA (20 mg/kg) + MTF (850-1500 mg/day) (n=13); NAC (1.2g) + MTF (850-1500 mg/day) (n=14) for 48 weeks. Clinical, laboratory and the second liver biopsies were performed after 48 weeks. RESULTS: A total of 53 patients were evaluated; 17 (32.1%) were males; median age ±54 (IQR=15, 21-71) years. In the baseline, no difference was seen between groups according clinical and histological parameters. The groups differed only in cholesterol, LDL and triglycerides. No significant differences in biochemical and histologic parameters were found between these the three groups after 48 weeks of treatment. In the intragroup analysis (intention-to-treat) comparing histological and biochemical features, there were significant improvements in the steatosis degree (P=0.014), ballooning (0.027) and, consequently, in the NAFLD Activity Score (NAS) (P=0.005), and in the ALT levels at the end of the treatment only in the NAC + MTF group. No significant evidence of modification in the liver fibrosis could be observed in any of the groups. CONCLUSION: This multicenter study suggests that the association of NAC + MTF could reduce the liver disease activity in patients with NASH. These data stimulate further controlled studies with this therapy for these patients.

RESUMO CONTEXTO: Atualmente, o tratamento farmacológico da doença hepática gordurosa não alcoólica (DHGNA) ainda é limitado e baseia-se no tratamento de condições associadas às comorbidades. O estresse oxidativo e a resistência à insulina são os mecanismos que parecem estar mais envolvidos em sua patogênese. OBJETIVO: Avaliar a eficácia da N-acetilcisteína (NAC) em associação à metformina (MTF) e/ou ácido ursodesoxicólico (UDCA) no tratamento da EHNA. MÉTODOS: Estudo randomizado, multicêntrico e aberto, conduzido por 48 semanas. Incluiu pacientes com esteato-hepatite não alcoólica (EHNA) comprovada por biópsia. Os pacientes foram distribuídos aleatoriamente em três grupos: NAC (1,2 g) + UDCA (15 mg/kg) + MTF (850-1500 mg/dia) (n=26); UDCA (20 mg/kg) + MTF (850-1500 mg/dia) (n=13); NAC (1,2 g) + MTF (850-1500 mg/dia) (n=14) durante 48 semanas. Os dados clínicos, laboratoriais e as segundas biópsias hepáticas foram realizados após 48 semanas. RESULTADOS - Um total de 53 pacientes foram avaliados; 17 (32,1%) eram do sexo masculino; idade mediana de ±54 (IQR=15, 21-71) anos. No baseline, nenhuma diferença foi observada entre os grupos de acordo com parâmetros clínicos e histológicos. Os grupos diferiram apenas em colesterol, LDL e triglicerídeos. Não foram encontradas diferenças significativas nos parâmetros bioquímicos e histológicos entre os três grupos após 48 semanas de tratamento. Contudo, na análise intragrupos (intenção de tratar) comparando características histológicas e bioquímicas, houve melhora significativa no grau de esteatose (P=0,014), balonização (P=0,027) e, consequentemente, no NAFLD Activity Score (NAS) (P=0,005), e nos níveis de ALT no final do tratamento apenas no grupo NAC+MTF. Nenhuma evidência significativa de modificaçãona fibrose hepática pôde ser observada em nenhum dos grupos. CONCLUSÃO: - Este estudo multicêntrico sugere que a associação de NAC+MTF poderia reduzir a atividade da doença hepática em pacientes com EHNA. Esses dados estimulam estudos adicionais controlados com essa terapia para esses pacientes.

Humans , Male , Female , Adolescent , Adult , Aged , Young Adult , Acetylcysteine/administration & dosage , Ursodeoxycholic Acid/administration & dosage , Non-alcoholic Fatty Liver Disease/drug therapy , Metformin/administration & dosage , Treatment Outcome , Drug Therapy, Combination , Middle Aged
Rev. Assoc. Med. Bras. (1992) ; 65(1): 33-37, Jan. 2019. tab
Article in English | LILACS | ID: biblio-985003


SUMMARY OBJECTIVE To investigate the clinical efficacy and the possible mechanisms of saxagliptin in the treatment of type 2 diabetes mellitus (T2DM) combined with non-alcoholic fatty liver disease (NAFLD). METHODS A total of 95 T2DM and NAFLD patients were randomly divided into group A (saxagliptin group), group B (glimepiride group), and group C (glimepiride combined with polyene phosphatidylcholine group). RESULTS After intervention treatment for 24 w, body mass index (BMI), waist-to-hip ratio (WHR), glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), fasting insulin (FINS), homeostatic model assessment of insulin resistance (HOMA-IR), interleukin-6 (IL-6), triglyceride (TG), total cholesterol (TC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (γ-GT), and quantitative detection of liver steatosis of study subjects were observed, the action of liver steatosis in subjects of groups A and C were significantly different from those of group B; however, there were no differences between groups A and C. The FINS, HOMA-IR, and IL-6 of subjects in group A was lower than those in groups B and C; however, there were no significant differences between the latter two groups. CONCLUSION For T2DM combined with NAFLD patients, the saxagliptin treatment could not only effectively control blood glucose but also attenuate insulin resistance and inflammatory injury of the liver to improve fatty liver further.

RESUMO OBJETIVO Investigar a eficácia clínica e os possíveis mecanismos da saxagliptina no tratamento do diabetes mellitus tipo 2 (DM2) associado à doença hepática gordurosa não alcoólica (DHGNA). MÉTODOS Um total de 95 DM2 combinados com pacientes com DHGNA foram aleatoriamente divididos em grupo A (grupo saxagliptina), grupo B (grupo glimepirida) e grupo C (glimepirida combinado com grupo fosfatidilcolina polienizada). RESULTADOS Após a intervenção tratamento por 24 w, índice de massa corporal (IMC), relação cintura-quadril (RCQ), hemoglobina glicada (HbA1c), glicemia de jejum (FPG), insulina de jejum (Fins), avaliação do modelo homeostático de insulina resistência (Homa-IR), interleucina-6 (IL-6), triglicérides (TG), colesterol total (CT), alanina aminotransferase (ALT), aspartato aminotransferase (AST), γ-glutamiltransferase (γ-GT) e detecção de esteatose hepática dos sujeitos do estudo foram observados. Ação de esteatose hepática de indivíduos nos grupos A e C foram significativamente diferentes do grupo B; no entanto, não houve diferenças entre os grupos A e C. Os grupos Fins, Homa-IR e IL-6 dos participantes do grupo A foram menores que os dos grupos B e C; no entanto, não houve diferenças significativas entre os dois últimos grupos. CONCLUSÃO Para o DM2 combinado com pacientes com DHGNA, o tratamento com saxagliptina pode não apenas controlar efetivamente a glicemia, mas também atenuar a resistência à insulina e a lesão inflamatória do fígado para melhorar ainda mais o fígado gorduroso.

Humans , Male , Female , Phosphatidylcholines/administration & dosage , Sulfonylurea Compounds/administration & dosage , Adamantane/analogs & derivatives , Diabetes Mellitus, Type 2/drug therapy , Non-alcoholic Fatty Liver Disease/drug therapy , Hypoglycemic Agents/administration & dosage , Blood Glucose , Insulin Resistance , Adamantane/administration & dosage , Body Mass Index , Treatment Outcome , Diabetes Mellitus, Type 2/complications , Dipeptides/administration & dosage , Non-alcoholic Fatty Liver Disease/complications , Middle Aged
Braz. j. med. biol. res ; 51(8): e7299, 2018. graf
Article in English | LILACS | ID: biblio-951744


Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with metabolic syndrome and can lead to life-threatening complications like hepatic carcinoma and cirrhosis. Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist antidiabetic drug, has the capacity to overcome insulin resistance and attenuate hepatic steatosis but the specific underlying mechanism is unclear. This study was designed to investigate the underlying molecular mechanisms of exenatide therapy on NAFLD. We used in vivo and in vitro techniques to investigate the protective effects of exenatide on fatty liver via fat mass and obesity associated gene (FTO) in a high-fat (HF) diet-induced NAFLD animal model and related cell culture model. Exenatide significantly decreased body weight, serum glucose, insulin, insulin resistance, serum free fatty acid, triglyceride, total cholesterol, low-density lipoprotein, aspartate aminotransferase, and alanine aminotransferase levels in HF-induced obese rabbits. Histological analysis showed that exenatide significantly reversed HF-induced lipid accumulation and inflammatory changes accompanied by decreased FTO mRNA and protein expression, which were abrogated by PI3K inhibitor LY294002. This study indicated that pharmacological interventions with GLP-1 may represent a promising therapeutic strategy for NAFLD.

Animals , Male , Rabbits , Peptides/pharmacology , Venoms/pharmacology , Protective Agents/pharmacology , Fatty Liver/metabolism , Non-alcoholic Fatty Liver Disease/drug therapy , Alpha-Ketoglutarate-Dependent Dioxygenase FTO/drug effects , Blood Glucose/analysis , Body Weight/drug effects , In Vitro Techniques , Gene Expression Regulation/drug effects , Morpholines/metabolism , Chromones/metabolism , Disease Models, Animal , Eating/drug effects , Enzyme Inhibitors/metabolism , Fatty Liver/pathology , Diet, High-Fat , Alpha-Ketoglutarate-Dependent Dioxygenase FTO/genetics , Exenatide , Insulin/blood , Malondialdehyde/analysis , Obesity/metabolism
Int. j. morphol ; 35(1): 345-350, Mar. 2017. ilus
Article in English | LILACS | ID: biblio-840976


Non-alcoholic fatty liver induces many complications to the liver tissue and also serum related parameters. Medicinal plants are the safe therapeutic strategy for the treatment of diseases. In this regards, the present study was conducted to evaluate the effect of Tribulus terrestris (T. terrestris) extract on non-alcoholic fatty liver in rats. In this experimental study, thirty male Wistar rats were divided into five groups (n=6). Animals in experimental groups were received high fructose diet (70 %) (HDF) daily alone or in combined with daily intraperitoneal injection of 500, 700 and 1000 mg/kg extract of T. terrestris. Control group of rats was feed with standard chow. The serum levels of biomarkers of liver and serum lipid profiles were assessed, also histopathological examination of liver tissue done. Data were analyzed using One-way ANOVA method followed by Tukey's post-hoc multiple comparison test and P<0.05 was considered statistically significant. There were significant improvements for biomarkers of liver tissue (P<0.05) and serum lipid profiles (P<0.01) in the HFD-fed rats that were treated with T. terrestris extract compare to HFD-fed group. In addition, accumulation of lipids in hepatocytes was significantly reduced in the HFD-fed + extract administrated groups in comparison to HFD-fed rats (P<0.01). T. terrestris extract has protective effects against non-alcoholic fatty liver by changing biomarkers of liver tissue, serum lipid profiles and histopathological anomalies of liver tissue, to normal range.

El hígado graso no alcohólico induce muchas complicaciones al tejido hepático y también en ciertos parámetros relacionados con el suero. Las plantas medicinales son la estrategia terapéutica segura para el tratamiento de enfermedades. En este sentido, el presente estudio se realizó para evaluar el efecto del extracto de Tribulus terrestris (T. terrestris) sobre el hígado graso no alcohólico en ratas. En este estudio experimental se dividieron 30 ratas macho Wistar en cinco grupos (n = 6). Los animales de los grupos experimentales recibieron dietas altas en fructosa (70 %) (HDF) al día o en combinación con inyección intraperitoneal diaria de 500, 700 y 1000 mg / kg de extracto de T. terrestris. El grupo control de ratas fue alimentado con alimento estándar. Se evaluaron los niveles séricos de biomarcadores hepáticos y perfiles de lípidos séricos, así como un examen histopatológico del tejido hepático. Los datos se analizaron utilizando el método ANOVA de una vía seguido de la prueba de comparación múltiple post-hoc de Tukey y el P<0,05 se consideró estadísticamente significativo. Hubo mejoras significativas en los biomarcadores del tejido hepático (P <0,05) y en los perfiles de lípidos séricos (P <0,01) en las ratas alimentadas con HFD que se trataron con extrato de T. terrestris comparado con el grupo alimentado con HFD. Además, la acumulación de lípidos en los hepatocitos se redujo significativamente en los grupos alimentados con HFD + extracto, en comparación con las ratas alimentadas con HFD (P <0,01). El extracto de T. terrestris tiene efectos protectores sobre el hígado graso no alcohólico, provocando modificaciones en los marcadores biológicos del tejido hepático, los perfiles lipídicos del suero y las anomalías histopatológicas del tejido hepático, hasta un rango normal.

Animals , Male , Rats , Non-alcoholic Fatty Liver Disease/drug therapy , Plant Extracts/therapeutic use , Tribulus/therapeutic use , Tribulus/chemistry , Plant Extracts/administration & dosage , Rats, Wistar , Tribulus/administration & dosage
An. bras. dermatol ; 91(6): 781-789, Nov.-Dec. 2016.
Article in English | LILACS | ID: biblio-837982


Abstract During the last decade, different studies have converged to evidence the high prevalence of comorbidities in subjects with psoriasis. Although a causal relation has not been fully elucidated, genetic relation, inflammatory pathways and/or common environmental factors appear to be underlying the development of psoriasis and the metabolic comorbidities. The concept of psoriasis as a systemic disease directed the attention of the scientific community in order to investigate the extent to which therapeutic interventions influence the onset and evolution of the most prevalent comorbidities in patients with psoriasis. This study presents scientific evidence of the influence of immunobiological treatments for psoriasis available in Brazil (infliximab, adalimumab, etanercept and ustekinumab) on the main comorbidities related to psoriasis. It highlights the importance of the inflammatory burden on the clinical outcome of patients, not only on disease activity, but also on the comorbidities. In this sense, systemic treatments, whether immunobiologicals or classic, can play a critical role to effectively control the inflammatory burden in psoriatic patients.

Humans , Psoriasis/drug therapy , Antibodies, Monoclonal/therapeutic use , Cardiovascular Diseases/drug therapy , Comorbidity , Risk Factors , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Metabolic Syndrome/drug therapy , Diabetes Mellitus/drug therapy , Dyslipidemias/drug therapy , Obesity, Abdominal/drug therapy , Non-alcoholic Fatty Liver Disease/drug therapy , Hypertension/drug therapy
Acta cir. bras ; 31(11): 706-713, Nov. 2016. tab, graf
Article in English | LILACS | ID: biblio-827661


ABSTRACT PURPOSE: To investigate the effect of curcumin on visfatin and zinc-α2-glycoprotein (ZAG) expression levels in rats with non-alcoholic fatty liver disease (NAFLD). METHODS: Fifty-six male rats were randomly divided into a control group (n=16) and model group (n=40) and were fed on a normal diet or a high-fat diet, respectively. Equal volumes of sodium carboxymethyl cellulose (CMC) were intragastrically administered to the control group for 4 weeks. At the end of the 12th week, visfatin and ZAG protein expression levels were examined by immunohistochemistry. Visfatin mRNA levels were measured by semi-quantitative reverse transcription polymerase chain reaction. RESULTS: Compared with the control group, the model group showed significantly increased expression of visfatin in liver tissue (P < 0.01) and significantly decreased expression of ZAG (P < 0.01). These effects were ameliorated by curcumin treatment. CONCLUSIONS: Visfatin and zinc-α2-glycoprotein may be involved in the pathogenesis of NAFLD. Treatment of NAFLD in rats by curcumin may be mediated by the decrease of visfatin and the increase of non-alcoholic fatty liver disease.

Animals , Male , Rats , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Curcumin/therapeutic use , Seminal Plasma Proteins/metabolism , Nicotinamide Phosphoribosyltransferase/metabolism , Fatty Acids/metabolism , Non-alcoholic Fatty Liver Disease/metabolism , Triglycerides/blood , Random Allocation , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Cholesterol/blood , Rats, Sprague-Dawley , Curcumin/administration & dosage , Alanine Transaminase/blood , Disease Models, Animal , Drug Evaluation, Preclinical , Non-alcoholic Fatty Liver Disease/drug therapy , Liver/pathology , Antioxidants/administration & dosage , Antioxidants/therapeutic use
Rev. gastroenterol. Perú ; 36(4): 336-339, oct.-dic. 2016. tab
Article in Spanish | LILACS | ID: biblio-991205


La esteatosis hepática no alcohólica (EHNA) está ampliamente distribuida a nivel mundial y es más frecuente en sujetos con dislipidemia, síndrome metabólico, obesos y con DM2 (34-74%). Sin embargo, la prevalencia de cirrosis por EHNA en la población general no se conoce, lo que es aún materia de investigación en nuestro medio. Objetivo: Determinar si existe diferencia significativa entre los parámetros metábólicos de esteatosis hepática no alcohólica en pacientes con diabetes tipo 2 de reciente diagnóstico controlados y no controlados. Material y métodos: Estudio retrospectivo de tipo caso control, realizado en el Hospital Guillermo Almenara Irigoyen, Lima - Perú, durante los meses de noviembre de 2014 a febrero de 2015. Constó de231 pacientes: 147 pacientes con DM2 de diagnóstico reciente con mal control glicémico y EHNA y 84 pacientes con DM2 de diagnóstico reciente con adecuado control y EHNA. Para el análisis estadístico se utilizó las pruebas de Levene para evaluar homogenidad de varianzas intragrupos y prueba paramétrica de t de student para muestras independientes. Resultados: Luego de aplicar la prueba de homogeneidad de Levene y el t de student para igualdad de medias los parámetros metabólicos significativos fueron el nivel de triglicéridos, el nivel de HbA1C, la dosis de metformina y el género. Conclusiones: Es importante en pacientes diabéticos diagnosticar EHGNA en forma temprana para un control más estricto, no sólo de la glucosa sérica sino de otros parámetros metabólicos, principalmente, los triglicéridos lo cual apoya fuertemente el concepto existente de "múltiples hits " que considera que la EHGNA afecta la homeostasis de la glucosa, y podría ser el punto de partida de nuevas investigaciones que permitan mejorar las intervenciones para reducir la progresión de la cirrosis en pacientes diabéticos y también retrasar la progresión de la diabetes mellitus en pacientes con esteatohepatitis no alcohólica.

Non-alcoholic fatty liver (NASH) is widely distributed around the world and is more common in subjects with dyslipidemia, metabolic syndrome obese and DM2 (34-74%). However, the prevalence of cirrhosis by NASH in general population is unknown which is still subject of research. Objective: To determine if there are significant differences between metabolic parameters of non-alcoholic fatty liver in controlled versus uncontrolled diabetes type 2 of recent diagnosis. Material and methods: retrospective case-control study, performed in the Hospital Guillermo Almenara Irigoyen, Lima, Peru from November 2014 to February 2015.This study included 231 patients: 147 patients (NASH with DM2 of recent diagnosis and poor control) and 84 patients (NASH with DM2 ofrecent diagnosis and adequate control). Statistical analysis: Levene test for evaluating homogeneity of variances intra groups and parametric test for independent samples. Results: After applying Levene test of homogeneity and student test, significant metabolic parameters were the triglycerides, HbA1C level, metformin dose and gender. Conclusions: It is important in diabetic patients to diagnose NASH early for a tighter control, not only of glucose but other metabolic parameters mainly triglycerides which strongly supports existing concept of "multiple hits" which considers NASH affects glucose homeostasis, and it could be the starting point of new research to improve interventions for decreasing progression from to cirrhosis in diabetic patients and also to delay progression of diabetes mellitus in patients with non alcoholic steatohepatitis.

Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Diabetes Mellitus, Type 2/complications , Non-alcoholic Fatty Liver Disease/blood , Triglycerides/blood , Glycated Hemoglobin/metabolism , Biomarkers/blood , Case-Control Studies , Retrospective Studies , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Non-alcoholic Fatty Liver Disease/complications , Non-alcoholic Fatty Liver Disease/drug therapy , Hypoglycemic Agents/therapeutic use , Metformin/therapeutic use
Gastroenterol. latinoam ; 27(supl.1): S55-S59, 2016. ilus, tab, graf
Article in Spanish | LILACS | ID: biblio-907655


Non-alcoholic fatty liver disease (NAFLD) represents an increasing health problem in Chile and worldwide. In some cases NAFLD presents with a progressive form that can lead to liver fibrosis, cirrhosis and hepatocellular carcinoma. Current pharmacological therapies (pioglitazone and vitamin E) show limited response and are associated to significant adverse effects. During recent years several novel and promising pharmacological therapies have been developed to prevent fibrosis, liver cirrhosis and reduce liver related deaths. The present article summarizes some of these promising strategies, including reported efficacy in clinical trials and associated adverse effects. Hopefully in the near future these new therapies will help to improve NAFLD management and reduce liver related complications.

El hígado graso no alcohólico (HGNA) es un creciente problema de salud pública en Chile y el mundo. En un subgrupo de sujetos, el HGNA puede presentarse con un fenotipo de daño hepático progresivo que puede evolucionar a fibrosis progresiva, cirrosis y carcinoma hepatocelular. Las estrategias farmacológicas actuales (pioglitazona y vitamina E) presentan eficacia limitada y no están exentas de efectos adversos. Durante los últimos años se han desarrollado múltiples estrategias farmacológicas novedosas y promisorias que buscan evitar la progresión hacia cirrosis y reducir la mortalidad de causa hepática. El presente artículo resume los principales nuevos fármacos, los efectos beneficiosos reportados y sus efectos adversos. Es de esperar que en un futuro próximo estas terapias permitan cambiar el pronóstico de nuestros pacientes con HGNA.

Humans , Chenodeoxycholic Acid/analogs & derivatives , Chenodeoxycholic Acid/therapeutic use , Liraglutide/therapeutic use , Non-alcoholic Fatty Liver Disease/drug therapy , Propionates/therapeutic use , Chalcones/therapeutic use , Liver Cirrhosis/prevention & control
Med. interna (Caracas) ; 31(4): 177-185, 2015. ilus
Article in Spanish | LILACS, LIVECS | ID: biblio-1009637


El Hígado graso no alcohólico (HGNA) se define como la infiltración grasa del hígado mayor al 5% de su peso incluyendo un amplio espectro de trastornos hepáticos que van desde la esteatosis simple hasta la esteatohepatitis pudiendo progresar a fibrosis, cirrosis, carcinoma hepatocelular y muerte. Para establecer el diagnóstico deben encontrarse hallazgos histológicos o imagenológicos, excluirse una causa secundaria de esteatosis y existir asociación con el Síndrome metabólico, en donde la Resistencia a la insulina es la piedra angular en su fisiopatología. Su prevalencia va en aumento de la mano con la epidemia de la obesidad a nivel mundial. La biopsia hepática sigue siendo el patrón de oro, sin embargo han surgido marcadores serológicos como índices predictivos de fibrosis así como métodos imagenológicos para lograr de manera no invasiva seleccionar a aquellos pacientes candidatos a biopsia hepática. El tratamiento de elección siguen siendo los cambios en el estilo de vida. La Vitamina E y las Tiazolidinedionas son los únicos que han demostrado evidencia en Ensayos Clínicos Controlados. Otros medicamentos serán discutidos así como drogas promisorias(AU)

Non-alcoholic fatty liver disease (NAFLD) is defined as fatty infiltration of the liver that is more than 5% of its weight including a wide spectrum of liver disorders ranging from simple steatosis to steatohepatitis, which can progress to fibrosis, cirrhosis, hepatocellular carcinoma and death. To establish the diagnosis histological or imaging findings to exclude a secondary cause of steatosis and have an association with metabolic syndrome, where insulin resistance is a cornerstone in its pathophysiology. Its prevalence is increasing with the obesity epidemic worldwide. Liver biopsy remains the gold standard; however serological markers have emerged as predictive indices of fibrosis and imaging methods to achieve noninvasively select candidates for liver biopsy. The treatment of choice remains the changes in lifestyle. Vitamin E and hiazolidinediones have shown evidence in Randomized Clinical Trials. Other medicines will be discussed as well as promising drugs. The present review aims to update the current information of this entity in terms of epidemiology, etiology, diagnosis and treatment(AU)

Humans , Metabolic Syndrome/physiopathology , Non-alcoholic Fatty Liver Disease/complications , Non-alcoholic Fatty Liver Disease/drug therapy , Internal Medicine , Liver Diseases , Metabolic Diseases
Article in English | WPRIM | ID: wpr-126670


Nonalcoholic steatohepatitis (NASH) can progress into liver cirrhosis; however, no definite treatment is available. Omega-3 polyunsaturated fatty acid (omega-3) has been reported to alleviate experimental NASH, although its beneficial effect was not evident when tested clinically. Thus, this study aimed to investigate the additive effect of omega-3 and ursodeoxycholic acid (UDCA) on diet-induced NASH in mice. C57BL/6 mice were given a high-fat diet (HFD) for 24 weeks, at which point the mice were divided into three groups and fed HFD alone, HFD with omega-3 or HFD with omega-3 in combination with UDCA for another 24 weeks. Feeding mice an HFD and administering omega-3 improved histologically assessed liver fibrosis, and UDCA in combination with omega-3 further attenuated this disease. The assessment of collagen alpha1(I) expression agreed with the histological evaluation. Omega-3 in combination with UDCA resulted in a significant attenuation of inflammation whereas administering omega-3 alone failed to improve histologically assessed liver inflammation. Quantitative analysis of tumor necrosis factor alpha showed an additive effect of omega-3 and UDCA on liver inflammation. HFD-induced hepatic triglyceride accumulation was attenuated by omega-3 and adding UDCA accentuated this effect. In accordance with this result, the expression of sterol regulatory binding protein-1c decreased after omega-3 administration and adding UDCA further diminished SREBP-1c expression. The expression of inducible nitric oxide synthase (iNOS), which may reflect oxidative stress-induced tissue damage, was suppressed by omega-3 administration and adding UDCA further attenuated iNOS expression. These results demonstrated an additive effect of omega-3 and UDCA for alleviating fibrosis, inflammation and steatosis in diet-induced NASH.

Animals , Male , Cholagogues and Choleretics/pharmacology , Diet, High-Fat/adverse effects , Drug Synergism , Fatty Acids, Omega-3/pharmacology , Fibrosis/drug therapy , Inflammation/drug therapy , Liver/drug effects , Mice, Inbred C57BL , Non-alcoholic Fatty Liver Disease/drug therapy , Ursodeoxycholic Acid/pharmacology
São Paulo; s.n; 2014. [93] p. ilus, tab, graf.
Thesis in Portuguese | LILACS | ID: biblio-870791


Introdução: Existem poucas estratégias de intervenção medicamentosa que se mostraram eficazes na doença hepática gordurosa não alcoólica (DHGNA). Os ácidos graxos poliinsaturados (AGPI) Ômega-3 parecem ser eficazes no tratamento da esteatose hepática de modelos experimentais, mas poucos estudos randomizados em humanos foram realizados. O objetivo deste estudo foi avaliar prospectivamente a eficácia de AGPI Ômega-3 provenientes do óleo de linhaça e peixe na esteatohepatite não alcoólica (pacientes com EHNA). Métodos: Sessenta pacientes com biópsia confirmando EHNA foram incluídos no estudo duplo cego, randomizado, placebo controlado. Os pacientes foram randomizados em dois grupos. Grupo Ômega-3 (n = 32) recebeu três cápsulas contendo no total 945 mg de AGPI Ômega-3 (63% ácido alfa linolênico (ALA), 21% ácido eicosapentaenóico (EPA) e 16% do ácido docosahexaenóico (DHA)) e Grupo Placebo (n = 28) recebeu três cápsulas contendo óleo mineral. A intervenção foi realizada por seis meses, quando os pacientes foram novamente submetidos à biópsia hepática. O desfecho primário foi a mudança histológica hepática de acordo com o escore de atividade EHNA (NAS) no início (pré intervenção) e seis meses (após intervenção). Desfecho secundário compreendeu análise das aminotransferases séricas, perfil lipídico e glicemia em jejum, parâmetros antropométricos e nível sérico de IL6 em 0, 3 e 6 meses e dosagem de Ômega-3 plasmático, como prova de tratamento, em 0 e 6 meses. Resultados: Dos 60 pacientes avaliados, 10 não terminaram o estudo (5 no grupo Ômega-3, e 5 no grupo placebo). Analisando os resultados primários, a atividade NAS melhorou ou se manteve estável em 78,26% dos pacientes do grupo placebo e em 55,56% do grupo Ômega-3, sem diferença significativa entre os grupos (p = 0,978), a inflamação lobular reduziu ou se manteve estável em 91,3% no grupo de placebo e em 66,67% no grupo Ômega-3, também sem diferença entre os grupos (p = 0,994). Ômega-3 não...

Introduction: There is a limited number of effective drug treatments available for the treatment of nonalcoholic steatohepatitis (NASH). Polyunsaturaturated fatty acid (PUFAs) Omega 3 seems to be effective in treating hepatic steatosis in experimental animal models, however there is a limited number of humans randomized studies available in the literature. The purpose of the present study is to prospectively evaluate the treatment efficacy of the PUFAs Omega 3 from flaxseed and fish in patients with NASH disease. Methods: A total of sixty biopsy confirmed NASH patients were included in a double blind, randomized, placebo controlled study. They were randomized into two groups: Omega 3 group (n = 32) where patients received a total of 945mg of PUFAs Omega 3 and Placebo group (n = 28) where patients received only mineral oil. After a 6 month treatment all patients underwent a new liver biopsy. Primary goal was to evaluate and compare liver histologic changes, according to Nonalcoholic fatty liver disease (NAFLD) activity score (NAS), between pre and post treatment biopsies. Secondary goal was to evaluate serum transaminases, lipid profile and serum non fasting glucose, anthropometric parameters and serum IL6 at 0, 3 and 6 month treatment. A serum Omega 3 dosage was performed at 0 and 6 month as treatment proof. Results: A total of 50 patients finished the study, 25 from each original group. NAS score improved or was unaltered in 78.26% of the placebo group and in 55.56% of the Omega 3 group (p = 0,978). Lobular liver inflammation was reduced or unaltered in 91.3% and in 66.67% respectively of the placebo and Omega 3 groups (p = 0,994). Omega 3 alone was not able to reduce liver steatosis, hepatocelular balonization or fibrosis. Biochemical analysis revealed reduction on serum triglycerides after 3 month treatment for the Omega 3 group patients, when compared to placebo (p=0,011). Serum transaminases, total cholesterol and fractions, non fasting...

Humans , Male , Female , Adolescent , Young Adult , Adult , Middle Aged , Aged , /therapeutic use , Non-alcoholic Fatty Liver Disease/drug therapy , Double-Blind Method , Evaluation of the Efficacy-Effectiveness of Interventions